Proteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDAC.

ABSTRACT:

Objectives

The aim is to investigate the proteomic profile of different molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) and understand their impact on patient outcomes, particularly focusing on pathways involved in xenobiotic metabolism and drug resistance.

Materials and methods

The study utilized the serum-free PACO cell culture model and a quantitative prefractionation-based MALDI/MS approach to establish the proteomic profiles of various PDAC subtypes. Differential protein regulation was analyzed to identify systematic alterations in metabolic and drug resistance pathways. Mechanistic studies involved the knockdown and overexpression of key proteins to assess their role in drug resistance.

Results

Proteomic analysis revealed subtype-specific alteratio

SUBMITTER: Thiel V 

PROVIDER: S-EPMC12713692 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature